Mobile

An open-label, randomized, multicenter study to evaluate the use of Zoledronic Acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer r...

Update Il y a 5 ans
Reference: EUCTR2004-001369-17

An open-label, randomized, multicenter study to evaluate the use of Zoledronic Acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapy

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To describe the percent in the lumbar spine (L2 to L4) BMD, as measured by dual energy X-ray absorptiometry(DXA), at 12 months in recently postmenopausal and postmenopausal women with hormone receptor positive breast cancer.

Inclusion criteria

  • Prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapy

Links